Tag: anti-VEGF

Novartis to file Lucentis for rare sight condition in premature babies

by Selina McKee | Sep 24, 2018 | News | 0

Novartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness.

High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin

by Selina McKee | Sep 24, 2018 | News | 0

Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.